Cargando…
Targeting KDM4B that coactivates c-Myc-regulated metabolism to suppress tumor growth in castration-resistant prostate cancer
Rationale: The progression of prostate cancer (PCa) to castration-resistant PCa (CRPC) despite continuous androgen deprivation therapy is a major clinical challenge. Over 90% of patients with CRPC exhibit sustained androgen receptor (AR) signaling. KDM4B that removes the repressive mark H3K9me3/2 is...
Autores principales: | Wu, Meng-Jen, Chen, Chih-Jung, Lin, Ting-Yu, Liu, Ying-Yuan, Tseng, Lin-Lu, Cheng, Mei-Ling, Chuu, Chih-Pin, Tsai, Huai-Kuang, Kuo, Wen-Ling, Kung, Hsing-Jien, Wang, Wen-Ching |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ivyspring International Publisher
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8315051/ https://www.ncbi.nlm.nih.gov/pubmed/34335964 http://dx.doi.org/10.7150/thno.58729 |
Ejemplares similares
-
Histone Demethylase KDM4C Stimulates the Proliferation of Prostate Cancer Cells via Activation of AKT and c-Myc
por: Lin, Ching-Yu, et al.
Publicado: (2019) -
KDM4B is a coactivator of c-Jun and involved in gastric carcinogenesis
por: Wu, Meng-Chen, et al.
Publicado: (2019) -
Inhibition of KDM4C/c‐Myc/LDHA signalling axis suppresses prostate cancer metastasis via interference of glycolytic metabolism
por: Lin, Ching‐Yu, et al.
Publicado: (2022) -
Natural product myricetin is a pan-KDM4 inhibitor which with poly lactic-co-glycolic acid formulation effectively targets castration-resistant prostate cancer
por: Liu, Jai-Shin, et al.
Publicado: (2022) -
New classification may assist the development of targeted therapies for treatment-refractory castration-resistant prostate cancer
por: Lin, Ching-Yu, et al.
Publicado: (2020)